Transforming growth factor β1 increase of hydroxysteroid dehydrogenase proteins is partly suppressed by red clover isoflavones in human primary prostate cancer-derived stromal cells

Carcinogenesis

Volumn 32, Issue 11, 2011, Pages 1648-1654

  Liu, Xunxian ^a   Piao, Yun Shang ^a   Arnold, Julia T ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; HYDROXYSTEROID DEHYDROGENASE; ISOFLAVONE DERIVATIVE; PRASTERONE; PROSTATE SPECIFIC ANTIGEN; RED CLOVER EXTRACT; TESTOSTERONE; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; COCULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; STEROID METABOLISM; STROMA CELL;

3-HYDROXYSTEROID DEHYDROGENASES; CELLS, CULTURED; ESTRADIOL DEHYDROGENASES; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; HYDROXYSTEROID DEHYDROGENASES; IMMUNOBLOTTING; IMMUNOPRECIPITATION; ISOFLAVONES; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; STROMAL CELLS; TESTOSTERONE; TRANSFORMING GROWTH FACTOR BETA1; TRIFOLIUM;

EID: 80755169515     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr206     Document Type: Article

References (27)

1. Bierie, B. et al. (2006) Tumour microenvironment - TGF: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer, 6, 506-520.
2. Yang, L. et al. (2010) TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol., 31, 220-227.
3. Peehl, D.M. et al. (1997) Induction of smooth muscle cell phenotype in cultured human prostatic stromal cells. Exp. Cell Res., 232, 208-215.
4. Tuxhorn, J.A. et al. (2001) Reactive stroma in prostate cancer progression. J. Urol., 166, 2472-2483.
5. Gilliver, S.C. et al. (2007) The hormonal regulation of cutaneous wound healing. Clin. Dermatol., 25, 56-62.
6. Dvorak, H.F. (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med., 315, 1650-1659.
7. Tuxhorn, J.A. et al. (2002) Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin. Cancer Res., 8, 2912-2923.
8. Untergasser, G. et al. (2005) Profiling molecular targets of TGF-beta1 in prostate fibroblast-to-myofibroblast transdifferentiation. Mech. Ageing Dev., 126, 59-69.
9. Gray, N.E. et al. (2009) Endocrine-immune-paracrine interactions in prostate cells as targeted by phytomedicines. Cancer Prev. Res. (Phila Pa), 2, 134-142.
10. Luu-The, V. et al. (2008) Androgen biosynthetic pathways in the human prostate. Best Pract. Res. Clin. Endocrinol. Metab., 22, 207-221.
11. Regelson, W. et al. (1994) Dehydroepiandrosterone (DHEA)-the "mother steroid". I. Immunologic action. Ann. N. Y. Acad. Sci., 719, 553-563.
12. Arnold, J.T. (2009) DHEA metabolism in prostate: for better or worse? Mol. Cell. Endocrinol., 301, 83-88.
13. Arnold, J.T. et al. (2008) Human prostate stromal cells stimulate increased PSA production in DHEA-treated prostate cancer epithelial cells. J. Steroid Biochem. Mol. Biol., 111, 240-246.
14. Weeraratna, A.T. et al. (2000) Rational basis for Trk inhibition therapy for prostate cancer. Prostate, 45, 140-148.
15. Liu, X. et al. (2008) Lycopene inhibits IGF-I signal transduction and growth in normal prostate epithelial cells by decreasing DHT-modulated IGF-I production in co-cultured reactive stromal cells. Carcinogenesis, 29, 816-823.
16. Chun, J.Y. et al. (2009) Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin. Cancer Res., 15, 4815-4822.
17. Le, H. et al. (2006) Dihydrotestosterone and testosterone, but not DHEA or estradiol, differentially modulate IGF-I, IGFBP - 2 and IGFBP-3 gene and protein expression in primary cultures of human prostatic stromal cells. Am. J. Physiol. Endocrinol. Metab., 290, E952-E960.
18. Liu, X. et al. (2005) Rapid, Wnt-induced changes in GSK3beta associations that regulate beta-catenin stabilization are mediated by Galpha proteins. Curr. Biol., 15, 1989-1997.
19. Liu, X. et al. (2011) Androgen-induced PSA expression requires not only activation of AR but also endogenous IGF-I or IGF-I/PI3K/Akt signaling in human prostate cancer epithelial cells. Prostate, 71, 766-771.
20. Massague, J. (2000) How cells read TGF-beta signals. Nat. Rev. Mol. Cell Biol., 1, 169-178.
21. Mitchell, H. et al. (2004) Ligand-dependent and -independent transforming growth factor-beta receptor recycling regulated by clathrin-mediated endocytosis and Rab11. Mol. Biol. Cell, 15, 4166-4178.
22. Bauman, D.R. et al. (2006) Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer. Endocrinology, 147, 5806-5816.
23. Pelletier, G. et al. (2001) Immunoelectron microscopic localization of 3betahydroxysteroid dehydrogenase and type 5 17beta-hydroxysteroid dehydrogenase in the human prostate and mammary gland. J. Mol. Endocrinol., 26, 11-19.
24. Carruba, G. et al. (1996) Steroid-growth factor interaction in human prostate cancer. 2. Effects of transforming growth factors on androgen metabolism of prostate cancer cells. Steroids, 61, 41-46.
25. Mizokami, A. et al. (2009) Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone. Endocr. Relat. Cancer, 16, 1139-1155.
26. Ludwig, C. et al. (2008) Evaluation of solvent accessibility epitopes for different dehydrogenase inhibitors. ChemMedChem, 3, 1371-1376.
27. Lee, C. et al. (1999) Transforming growth factor-beta in benign and malignant prostate. Prostate, 39, 285-290.